Showing results (6791-6800 of 10,083) with videos related to
Sort By:
Pageof 1,009
Current Pharmaceutical Design|December 23, 2011
New insights into redox-modulated cell signalingGabriella Leonarduzzi, Barbara Sottero, Gabriella Testa, et al.Current Pharmaceutical Design|December 23, 2011
Protein oxidative modification in the aging organism and the role of the ubiquitin proteasomal systemMarc Kastle, Tilman GruneCurrent Pharmaceutical Design|January 16, 2013
The promise of cholesteryl ester transfer protein (CETP) inhibition in the treatment of cardiovascular diseaseA E Bochem, J A Kuivenhoven, E S G StroesCurrent Pharmaceutical Design|January 16, 2013
Apolipoprotein B antisense inhibition--update on mipomersenCatherine Gebhard, Gabriel Huard, Ekaterini A Kritikou, et al.Current Pharmaceutical Design|January 16, 2013
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologiesNabil G SeidahCurrent Pharmaceutical Design|December 12, 2012
Safety and efficacy of bridging with low molecular weight heparins: a systematic review and partial meta-analysisPieter Eijgenraam, Hugo ten Cate, Arina Ten Cate-HoekCurrent Pharmaceutical Design|December 15, 2012
Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomersHarish Rajak, Pramod Kumar Dewangan, Vijay Patel, et al.Current Pharmaceutical Design|December 25, 2012
Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunyaAnjali Soni, Khushhali M Pandey, Pratima Ray, et al.Current Pharmaceutical Design|December 25, 2012
Selectivity, binding affinity, and ionization state of matrix metalloproteinase inhibitorsHaizhen A Zhong, Jack Arbiser, J Phillip BowenCurrent Pharmaceutical Design|December 25, 2012
Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancementsMinhajul Arfeen, Prasad V BharatamPageof 1,009